Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. (Q39472188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

S Fruchon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Kheirallah

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

T Al Saati

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

L Ysebaert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Laurent

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

L Leseux

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Laurent

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Bezombes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

16 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

795-805

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.248

12 February 2020

exact match

0 references

cites work

Syk-dependent mTOR activation in follicular lymphoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Membrane-associated signaling in human B-lymphoma lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Spleen tyrosine kinases: biology, therapeutic targets and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Syk and pTyr'd: Signaling through the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Matrix metalloproteinases and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Matrix metalloproteinases as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Matrix metalloproteinases: regulators of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Regulation of Akt-dependent cell survival by Syk and Rac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Signal transduction inhibitor therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

RhoC Promotes Metastasis via Activation of the Pyk2 Pathway in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

The Vav binding site of the non-receptor tyrosine kinase Syk at Tyr 348 is critical for beta2 integrin (CD11/CD18)-mediated neutrophil migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

A critical role for Syk in endothelial cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.248

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21926965%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference